3 ms·
Nice. This tells me that research on the drug is old and that increases security on its use.
by hu3 10mo ago
Nice.
This tells me that research on the drug is old and that increases security on its use.
- stavros 10mo agoIt's so old, the patent is nearing expiration.
- wombatpm 10mo agoThat’s usually the case for new classes of drugs.
- scheme271 10mo agoThe first generation of GLP-1 agonists are out of patent protection. Teva is producing a generic liraglutide (aka Victoza / Saxenda). Ozempic (semiglutide) and Mounjaro (tirzepatide) have protection until after 2031 in the US, I think it's less in other countries.
- epistasis 10mo agoGLP-1 is a drug target, not a drug. It's actually a hormone. There are many drugs that have been developed since then, and each approval seems to have slightly better drug properties. The age of research on a drug is not very indicative of safety, either. Rather, broad study and time are far better. I'd take five years of clinical trials on hundreds of thousands of people over 5000 years old research on hundreds of people.
- refurb 10mo agoNot necessarily. If it just sits on a shelf, there is no new data on it's use in humans.